It’s been a volatile last few months for Mountain Valley MD Holdings (CNSX:MVMD) (OTCMKTS:MVMDF) share price for both positive and less savory reasons. Trading at less than C$0.10 per share in early December, a positive news cycle and substantial investor interest helped propel the stock to a closing high of C$2.19 per share following its OTCQB Exchange listing last month. However in recent times, its shares have come under pressure despite a continuing flow of material announcements.
Most recently, Mountain Valley MD announced it was commencing husbandry animal trials for the company’s injectable solubilized Ivermectin technology (Ivectosol™ 1%) under the supervision of The People’s Republic of Bangladesh’s Ministry of Fisheries & Livestock. If the month-long study goes well, the company believes significant commercializing opportunities will unlock in South Asia markets to parasitic diseases in livestock such as cattle, swine, goats and poultry—an addressable market size of more than 67 billion animals.
In the United States, Ivermectin is already FDA-approved for use in animals for prevention of heartworm disease in some small animal species, and for treatment of certain internal and external parasites in various animal species.
While the continuous flow of good news is something Mountain Valley MD investors have come to expect, Dennis Hancock opens the interview with a scathing rebuke of the recent Night Market Research short report (which we won’t dignify with a hyperlink):
I saw it was circulated. Very malicious, you know, full of fraudulent detail. We’re going to have legal deal with that separately… My joking side would say I’m surprised there’s even WIFI down in the sewers where that document was written. If I were to get serious about what we’re doing and why that is so irrelevant—anyone doing something for their personal gain in an anonymous report and going through all of those sort of, you know, fake accusation clearly, you know, the worst journalism I’ve ever seen.Dennis Hancock, President & CEO Mountain Valley MD Holdings
Beyond the opening salvo, Dennis provides concise details of the research Mountain Valley MD is conducting and the headway it is making by solubilizing the insoluble. An interview not to be missed.